Merck halts Gardasil shipments to China, withdraws $11B sales target as demand nosedives
The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is halting shipments to the world’s second-most populous country. | The recent decline of Merck & Co.
Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...
Merck's stock sank after the company reported fourth-quarter and year-end 2024 earnings this morning. Although it narrowly ...
Merck reported a 2% decline in Gardasil sales, after reaching a peak of $8.9 billion in 2023. Now with shipments to China paused, the HPV vaccine faces significant headwinds going into 2025.
Gardasil, which prevents cancers caused by the human papillomavirus, has been one of Merck's top growth drivers aside from Keytruda, and much of its international growth had come from China before ...
Merck (MRK) shares drop 8% premarket as 2025 outlook falls short of Wall Street estimates, despite beating Q4 expectations ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...
Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of foreign exchange, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback